Poolbeg Pharma consortium wins grant to develop oral vaccines
The company said it is continuing to target further non-dilutive funding opportunities
Company
Poolbeg Pharma PLC
LON:POLB
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
134 stories · page 2 of 2
Poolbeg Pharma and partner find first RSV drug targets using AI
It partnered with OneThree Biotech to carry out the research
Poolbeg Pharma CEO buys stock in the drug developer
Jeremy Skillington bought 718,733 shares at 4.78p each
Poolbeg Pharma enhances the patent protection around flu asset
The company expects to receive the formal US patent grant "in due course"
Poolbeg Pharma signs exclusive deal with University College Dublin for vaccine candidate
POLB 003 is a prospective treatment to prevent Melioidosis
Poolbeg Pharma has made significant progress, says upbeat City broker
The company's corporate broker finnCap pointed to a series of potential inflexion points for the drug developer
Poolbeg Pharma eyes busy second half as value inflexion point nears
POLB 001, a treatment for severe flu, is the company's most advanced asset
Archive
Small Cap Movers: Poolbeg Pharma surges as flu trial begins
Some of the biggest movers up and down on Aim over the past week
Poolbeg Pharma says green light for flu drug trial is a 'major milestone'
Researchers will formally commence the trial of POLB 001 on July 22
Poolbeg Pharma partner completes AI model using RSV challenge trial data
A model will be built to discover and identify the disease signatures that define RSV infection
Small cap movers: Poolbeg Pharma has patently strong week while ANGLE sees acute rise
A look at some of the major movers in the small-cap world this week
Poolbeg Pharma hails US patent office success; says it marks an important step towards commercialising assets
It has secured protection for two key assets - POLB 001 and POLB 002
Poolbeg Pharma appoints a drug manufacturer ahead of its flu trial next month
POLB 001 is being developed to reduce the body's hyperinflammatory response to the severe form of the virus
Poolbeg Pharma receives European patent protection for key asset
POLB 002 is a nasally administered treatment with the potential to protect against respiratory virus infections
Poolbeg Pharma says share sale will widen the investor base and increase future liquidity
One of the buyers is an experienced life sciences investor
Poolbeg Pharma inks clinical trial agreement for influenza asset
It is working with the Centre for Human Drug Research with the human challenge study getting underway in June
Poolbeg Pharma signs deal with AI company that will help it better interrogate its human challenge data
The life sciences group is teaming up with CytoReason
Poolbeg Pharma announces AGM date
The clinical-stage infectious disease pharmaceutical company also posted a voting proxy form to its shareholders
Poolbeg Pharma reports progress on multiple fronts alongside maiden full year results
The company had £20.9mln on the balance sheet at the end of the period and is also evaluating opportunities for non-dilutive grant funding to support the development of its pipeline
Archive
Small Cap Wrap - Trifast, Tirupati Graphite, Tertiary Minerals and more...
Tertiary Minerals 0.2p £3.15m (LON:TYM) The mineral exploration and development company, whose strategic focus is on energy transition and precious metals announced that contractors have been appointed for the Company's upcoming drill progr
Poolbeg Pharma breaking new ground with its use of AI in developing new RSV drugs
It has partnered with OneThree Biotech, a pioneer of artificial intelligence in the drugs arena
Poolbeg Pharma licensing agreement gives it access to AnaBio microencapsulation and nanoencapsulation technologies
The deal looks to be a prelude to creating and offering oral vaccines
Poolbeg Pharma underlines ambitions with second anti-infective licensing deal, says analyst
It is noteworthy that Poolbeg has been able to obtain rights to these products against the background of anti-infectives coming back into focus
Poolbeg Pharma strikes in-licensing deal with the University of Warwick
The company will add to its pipeline a potential immunotherapy for respiratory virus infections
Poolbeg Pharma partnership to focus on creating the next generation of oral vaccines
While anti-vaxxers continue to rail against mass inoculation, a major impediment to compliance continues to be the use of needles to administer the protection against the virus
Poolbeg Pharma inks option agreement with University College Dublin for melioidosis vaccine
Also known as Whitmore's disease, melioidosis is found in the soil and surface groundwater of many tropical and subtropical regions, causing pneumonia and severe sepsis with multiple organ abscesses
Poolbeg Pharma appoints infectious disease expert to scientific advisory board
Professor Daniel Hoft has 32 years of experience and has published over 140 peer-reviewed articles
Poolbeg Pharma building a "conveyor belt of out licensing” says chairman
The company has set Germany drug business Evotec as the benchmark
Poolbeg Pharma plans phase Ib trial for influenza drug next summer
POLB 001 is what’s called an immunomodulator, which means it helps fight infection. It is being developed to treat severe flu
Poolbeg Pharma makes patent applications to protect its virus diagnostic platform
PredictViral is being developed to be used to detect respiratory viruses such as influenza, respiratory syncytial virus and human rhinoviruses that cause over half of all common colds
Poolbeg Pharma to work with Eurofins Genomics on RNA sequencing programme
The collaboration with Eurofins is a ‘key step’ to commencing artificial intelligence analysis of its data and will mean it then has full immunological datasets for respiratory syncytial virus
Poolbeg Pharma making US patent progress
Chief executive Jeremy Skillington said: "Our US patent assessment is going to plan and we look forward to updating our shareholders when we receive confirmation of its grant."
Archive
Botswana Diamonds boosted by Vast Resources' acquisition of the Ghaghoo diamond mine
A look at some of the major movers in London on Monday
Poolbeg Pharma shares rise on first day of AIM dealings
He said the company’s capital-light model has been well received by investors, said chief executive Jeremy Skillington